Clinical Trial Detail

NCT ID NCT04225117
Title A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Astellas Pharma Global Development, Inc.
Indications

stomach cancer

gastroesophageal cancer

lung non-squamous non-small cell carcinoma

Advanced Solid Tumor

head and neck cancer

triple-receptor negative breast cancer

esophageal cancer

Her2-receptor negative breast cancer

lung non-small cell carcinoma

Therapies

Enfortumab vedotin-ejfv

Age Groups: adult senior

No variant requirements are available.